Hepatocyte-intrinsic innate immunity in hepatitis B virus infection: A focused review

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=2

Jun 27, 2025 (publication date) through Jun 25, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jun 27, 2025; 17(6): 104533
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.104533

Table 1 Current anti-hepatitis B virus candidate therapeutics based on innate immunity

Drug name	Target	Sponsor	Phase	Ref.
Vesatolimod	TLR7 agonist	Gilead	II	[87]
Ruzotolimod	TLR7 agonist	Roche	II	[88]
JNJ-64794964 (JNJ-4964/AL-034/TQ-A3334)	TLR7 agonist	Chia Tai Tianqing/Janssen	II	[95]
Selgantolimod	TLR8 agonist	Gilead	II	[89,90]
Cavrotolimod	TLR9 agonist	Bluejay	I	[96]
Inarigivir	RIG-I agonist	Spring bank/Gilead	II (terminated)	[91]
Recombinant IL2	IL2	University of Science and Technology of China	Investigator-Initiated Trial	[85]

TLR: Toll-like receptor; RIG-I: Retinoic acid-inducible gene I; IL2: Interleukin-2.

Citation: Chen P, Zhao J, Chen NK, Chen ZY. Hepatocyte-intrinsic innate immunity in hepatitis B virus infection: A focused review. World J Hepatol 2025; 17(6): 104533
URL: https://www.wjgnet.com/1948-5182/full/v17/i6/104533.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i6.104533